This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Compare 2024 dividend aristocrats ETF fees to find the lowest cost option. This guide highlights expense ratios and what to look for in a low-cost fund.
27,654 articlesA notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Insider moves can signal confidence, but they aren’t a surebet. This guide shows you how to interpret a director purc...
A new Ethereum-based play-to-earn title, Meme Punch, launches its medieval arena with MEPU rewards. The game blends m...
When geopolitics collide with global manufacturing, one top EV maker shows how to turn risk into growth. This story d...
A new tech challenger aims to blend space, AI, and hardware into one powerful growth engine. This article breaks down...
Developers race to add native privacy to Ethereum as investors rotate into privacy-first assets. A 12-month deadline ...
Realtracs warns of a June 1 cutoff for the Zillow feed unless updated IDX rules are met. The move could remake listin...
AI is accelerating frontline work even as executive teams struggle to adapt. Leaders must redesign decision-making to...
USD Private unveils a closed digital asset platform featuring a programmed price path from $1 to $1 million over four...
As the US Treasury aims to rebuild its cash balance toward 900B by June, Bitcoin traders face a potential liquidity s...
SpaceX's planned IPO could be the largest ever, drawing Gulf sovereign funds into tech-heavy bets and reshaping globa...
Debt service is eating a growing share of tax receipts, and new projections warn of a 2032 Social Security funding cr...